Lazard Asset Management
RCUS icon

Lazard Asset Management’s Arcus Biosciences RCUS Stock Holding History

Lazard Asset Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,261
Closed -$93K – 2531
2024
Q4 		$93K Buy
6,261
+6,078
+3,321% +$99.3K ﹤0.01% 1822
2024
Q3 		$2K Sell
183
-5,679
-97% -$89.5K ﹤0.01% 2096
2024
Q2 		$89K Buy
+5,862
New +$94.6K ﹤0.01% 1785
2023
Q4 		– Sell
-3,960
Closed -$71K – 2428
2023
Q3 		$71K Buy
+3,960
New +$79.6K ﹤0.01% 1755
2023
Q1 		– Sell
-6,415
Closed -$132K – 2504
2022
Q4 		$132K Hold
6,415
– – ﹤0.01% 1420
2022
Q3 		$167K Buy
6,415
+3,979
+163% +$105K ﹤0.01% 1312
2022
Q2 		$61K Hold
2,436
– – ﹤0.01% 1724
2022
Q1 		$76K Buy
+2,436
New +$81.6K ﹤0.01% 1524
2021
Q1 		– Sell
-2,645
Closed -$68K – 1988
2020
Q4 		$68K Buy
+2,645
New +$64K ﹤0.01% 1292

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Lazard Asset Management's RCUS Position: Q1 2025 in Review

Lazard Asset Management sold out of Arcus Biosciences (RCUS) in Q1 2025, closing a stake of 6,261 shares — an estimated $93K sold.

Lazard Asset Management first reported a position in RCUS in Q4 2020 and held it in 9 quarters. The position peaked at $167K in Q3 2022. 186 funds tracked by Wall St. Rank hold RCUS as of Q1 2025.

  • Lazard Asset Management reported no remaining Arcus Biosciences position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 6,261 Arcus Biosciences shares in Q1 2025, an estimated $93K.
  • Lazard Asset Management first reported a position in Arcus Biosciences in Q4 2020 and held it in 9 quarters.
  • Lazard Asset Management's Arcus Biosciences position peaked at $167K in Q3 2022.
  • 186 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.